hematopoietic stem cells

[Experimental Hematology] Scientists present a summary and discussion of the implications of new approaches to improve hematopoietic stem cell transplantation-based therapy.

[Celularity, Inc.] Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).

[BMC Cancer] Investigators retrospectively collected the clinical data of 48 patients with mixed-lineage leukemia (MLL)-partial tandem duplications (PTD) acute myeloid leukemia or myelodysplastic syndrome with excess blasts who underwent allogeneic hematopoietic stem cell transplantation (HSCT) in Peking University People’s Hospital.

[Blood Advances] The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific T cell engager molecule, for treatment of pediatric relapsed/refractory B cell precursor acute lymphoblastic leukemia were examined in an open-label, single-arm, expanded access study (RIALTO).

[Cellular and Molecular Life Sciences] Researchers showed that HematoMiRs and their combinations targeting over 50 factors involved in HSC quiescence could induce robust ex vivo murine and human HSC expansion. In particular, HematoMiR-5 treatment enhanced cell cycle through down-regulation of negative cell cycle regulators in HSCs.

[Blood Advances] Scientists summarize the literature on post-hematopoietic stem cell transplantation immune-mediated anemia with a focus on ABO and non-ABO blood group incompatibility, described the underlying mechanism of anemia, and outlined preventive and treatment approaches.